
Cell and gene therapies – looking forward
Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More

Drug Discovery World speaks to key players in the cell and gene therapy sector to learn about the opportunities and challenges in this promising but difficult treatment area. … Read More

DDW covers some of the biggest announcements from the second day of SLAS2026. Emulate showcases organ-chip platform at SLAS2026 Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform. Read more… Charles River and… Read More

The London Cancer Hub has secured approval for a £1 billion ($1.4 billion) expansion, bringing state-of-the-art cancer research and lab space to the UK. London Cancer Hub’s expanded district promises to be one of the world’s most ambitious life sciences clusters, with 12 acres dedicated to accelerating cancer research, treatment and commercial… Read More

Manufacturer Omega Bio-tek has presented a new workflow offering a high-throughput, automation-friendly platform at SLAS2026. The workflow, developed in collaboration with Dynamic Devices, integrates the M1272 Mag-Bind Endo-free Plasmid Midi Kit. It is designed to meet the growing demand for scalable, endotoxin-free plasmid purification, which the company says is suitable for sensitive downstream applications including transfection, viral… Read More

UniteLabs has presented its Operating System at SLAS2026, promising to unlock AI-ready lab automation. The Operating System replaces vendor-specific instruments and software with an open, Python-based infrastructure, giving lab automation engineers and scientists full control and transparency over their workflows. Use cases at launch included liquid handling and closed loop… Read More

Cenevo has advanced towards agentic labs with the launch of two new AI agents. The company, which specialises in lab management systems, automation, orchestration, data management and AI technology for life sciences, hopes the new agents will help scientists operate faster, smarter and with less manual overhead. The first new agent,… Read More

Promega has launched a new live-cell target engagement platform aiming to close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. TheTarSeer BRETSA Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. … Read More

QIAGEN has presented its new high-throughput sample processing system at SLAS2026. The QIAsprint Connect marks the company’s entry into high-throughput sample processing, enabling preparation of up to 192 samples per run while reducing plastic consumption. QIAGEN hopes the system can address demand for automation and throughput in applications,… Read More

Charles River Laboratories has announced a collaboration with software and assay developer Synthace to advance assay development in drug discovery. As part of the collaboration announced at SLAS2026, Charles River will give its clients access to Synthace’s approach to developing, automating and transferring more robust assays, which it says are faster and… Read More

Emulate has brought its AVA Emulation System to SLAS2026, showcasing the potential to accelerate drug development with a first-of-its-kind high-throughput organ-chip platform. The AVA Emulation System, launched in June 2025, is a self-contained instrument that cultures, incubates, and images up to 96 independent organ-chip samples in… Read More

DDW covers some of the biggest announcements from the first day of SLAS2026. Carterra launches high-throughput SPR instrument High-throughput technology provider Carterra launched its Carterra Vega High-Throughput Surface Plasmon Resonance (HT-SPR) instrument – the industry’s first 48-channel SPR platform. The instrument has been designed to deliver 12-fold higher throughput versus the… Read More

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

Biotech company Shanghai Lishan has entered a licensing agreement with computational chemistry company Evogene for a treatment enhancing immunotherapy response. BMC128, a potential first-in-class, microbiome-based therapeutic, is designed to enhance anti-tumour activity. The treatment, developed by Evogene’s subsidiary Biomica, is a live biopharmaceutical consortium composed of four human gut… Read More

Biopharmaceutical company Kainova Therapeutics has secured $32 million CAD (US $24 million) to accelerate the development of immuno-oncology and inflammation therapies. This financing round was led by Investissement Québec, with funds set to support Kainova’s advancement of GPCR-targeting therapies. The company’s lead asset DT-7012, a Treg-depleting anti-CCR8 antibody,… Read More

The US Senate has reauthorised the US Food and Drug Administration (FDA)’s Priority Review Voucher (PRV), helping biotech companies to develop rare disease drugs. The PRV programme, which incentivises rare disease drug development, was reauthorised on 30 January, with President Donald Trump signing the bill. … Read More

Revvity launched multiple new discovery platforms and technologies at SLAS2026, all designed to accelerate high-throughput drug discovery workflows. The company debuted its Opera Phenix OptIQ high-content screening system, the EnVision Nexus One multimode plate reader, and the AssayMate workstation. The Opera Phenix OptIQ high-content screening system is designed to reduce bottlenecks in phenotypic screening and… Read More